We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

J.P.Morgan keeps AstraZeneca as 'top pick' on growth outlook, undervaluation

Thu 21 October 2021 11:21 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - AstraZeneca's growth outlook is the best in its sector and was not yet reflected in its share price, analysts at JP Morgan said following a 'deep dive' into the drug maker's financials.

Hence their decision to keep the shares as their 'top pick' in the sector.

In local currency terms, the broker estimated that the company's core earnings per share were set to grow by 33%, 27% and 23% between 2021-23 - excluding its Covid-19 vaccine.

Subsequently, EPS was seen growing at a compound annual rate of growth of 9% over 2023-26.

Furthermore, Astra was only trading on 14.5 times' its estimated core EPS for 2023, against its sector trading on 16.5.

Yet the expected rate of growth in the drugmaker's core EPS across 2023-26 in compound annual terms was expected to be four percentage points higher thanks to its comparatively young on-market portfolio and deep late stage pipeline.

"Given our forecast for a strong growth outlook, and the compelling valuation, we remain Overweight, with Astra remaining a top pick in the sector."

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More stockbroker tips from ShareCast

    Latest economy and stock market articles